FDAnews
www.fdanews.com/articles/159862-nanotherapeutics-begins-patient-enrollment-in-phase-ii-trial-of-triapine

Nanotherapeutics Begins Patient Enrollment in Phase II Trial of Triapine

November 5, 2013
U.S.-based biopharmaceutical company Nanotherapeutics has started enrollment of first patient in a Phase II cervical cancer trial for Triapine, a ribonucleotidereductase inhibitor.
Pharmaceutical Business Review